[1] BAGCCHI S. WHO’s Global Tuberculosis Report 2022. Lancet Microbe. 2023;4(1):e20.
[2] 徐彩红,赵雁林.从《2020年全球结核病报告》看我国结核病防治工作[J].中华传染病杂志,2021,39(7):392-397.
[3] AGASHE VM, JOHARI AN, SHAH M, et al. Diagnosis of Osteoarticular Tuberculosis: Perceptions, Protocols, Practices, and Priorities in the Endemic and Non-Endemic Areas of the World-A WAIOT View.Microorganisms. 2020;8(9):1312 .
[4] KHANNA K, SABHARWAL S. Spinal tuberculosis: a comprehensive review for the modern spine surgeon. Spine J. 2019;19(11):1858-1870.
[5] 章权,石仕元,王自立.我国脊柱结核病外科治疗现状及进展[J].中国脊柱脊髓杂志,2022,32(1):75-79.
[6] RAJASEKARAN S, SOUNDARARAJAN DCR, SHETTY AP, et al. Spinal Tuberculosis: Current Concepts. Global Spine J. 2018;8:96S-108S.
[7] SCHWARZ EM, PARVIZI J, GEHRKE T, et al. 2018 International Consensus Meeting on Musculoskeletal Infection: Research Priorities from the General Assembly Questions. J Orthop Res. 2019;37(5):997-1006.
[8] WHO consolidated guidelines on tuberculosis: Module 4: Treatment - Drug-susceptible tuberculosis treatment [Internet]. Geneva: World Health Organization. 2022.
[9] HU J, LI X, CHEN Y, et al. The protective effect of WKYMVm peptide on inflammatory osteolysis through regulating NF-κB and CD9/gp130/STAT3 signalling pathway. J Cell Mol Med. 2020;24(2):1893-1905.
[10] DENG J, YANG Y, HE J, et al. Vitamin D receptor activated by vitamin D administration alleviates Mycobacterium tuberculosis-induced bone destruction by inhibiting NFκB-mediated aberrant osteoclastogenesis.FASEB J. 2021;35(6):e21543.
[11] LIU X, JIA W, WANG H, et al. Establishment of a rabbit model of spinal tuberculosis using Mycobacterium tuberculosis strain H37Rv. Jpn J Infect Dis. 2015;68(2):89-97.
[12] TANG L, WU M, LU S, et al. Fgf9 Negatively Regulates Bone Mass by Inhibiting Osteogenesis and Promoting Osteoclastogenesis Via MAPK and PI3K/AKT Signaling. J Bone Miner Res. 2021;36:779-791.
[13] PENG Q, MALHOTRA S, TORCHIA JA, et al. TREM2- and DAP12-dependent activation of PI3K requires DAP10 and is inhibited by SHIP1.Sci Signal. 2010;3(122):ra38.
[14] GYŐRI D, CSETE D, BENKŐ S, et al. The phosphoinositide 3-kinase isoform PI3Kβ regulates osteoclast-mediated bone resorption in humans and mice. Arthritis Rheumatol. 2014;66(8):2210-2221.
[15] SANTOS MS, LIMA VTM, BARRIONI BR, et al. Targeting phosphatidylinositol-3-kinase for inhibiting maxillary bone resorption.J Cell Physiol. 2023;238(11):2651-2667.
[16] WEI L, CHEN W, HUANG L, et al. Alpinetin ameliorates bone loss in LPS-induced inflammation osteolysis via ROS mediated P38/PI3K signaling pathway. Pharmacol Res. 2022;184:106400.
[17] CHEN X, CHEN W, AUNG ZM, et al. LY3023414 inhibits both osteogenesis and osteoclastogenesis through the PI3K/Akt/GSK3 signalling pathway. Bone Joint Res. 2021;10(4):237-249.
[18] SALHOTRA A, SHAH HN, LEVI B, et al. Mechanisms of bone development and repair. Nat Rev Mol Cell Biol. 2020;21(11):696-711.
[19] HU K, SHANG Z, YANG X, et al. Macrophage Polarization and the Regulation of Bone Immunity in Bone Homeostasis. J Inflamm Res. 2023;16:3563-3580.
[20] MA W, JIN W, HE X, et al. Mycobacterium tuberculosis Induced Osteoblast Dysregulation Involved in Bone Destruction in Spinal Tuberculosis. Front Cell Infect Microbiol. 2022;12:780272.
[21] BAE S, KIM K, KANG K, et al. RANKL-responsive epigenetic mechanism reprograms macrophages into bone-resorbing osteoclasts. Cell Mol Immunol. 2023;20(1):94-109.
[22] SUN Y, LI J, XIE X, et al. Recent Advances in Osteoclast Biological Behavior. Front Cell Dev Biol. 2021;9:788680.
[23] ASAGIRI M, TAKAYANAGI H. The molecular understanding of osteoclast differentiation. Bone. 2007;40(2):251-64.
[24] JIANG W, JIN Y, ZHANG S, et al. PGE2 activates EP4 in subchondral bone osteoclasts to regulate osteoarthritis. Bone Res. 2022;10(1):27.
[25] BEDARD M, VAN DER NIET S, BERNARD EM, et al. A terpene nucleoside from M. tuberculosis induces lysosomal lipid storage in foamy macrophages. J Clin Invest. 2023;133(6):e161944.
[26] 王瀚,曹新生,张舒.破骨细胞体外培养技术[J].中国骨质疏松杂志,2014,20(11):1284-1289.
[27] ZANG L, KAGOTANI K, NAKAYAMA H,et al. 10-Gingerol Suppresses Osteoclastogenesis in RAW264.7 Cells and Zebrafish Osteoporotic Scales. Front Cell Dev Biol. 2021;9:588093.
[28] ONO T, NAKASHIMA T. Recent advances in osteoclast biology. Histochem Cell Biol. 2018;149:325-341.
[29] PARK JH, LEE J, LEE GR, et al. Cholesterol sulfate inhibits osteoclast differentiation and survival by regulating the AMPK-Sirt1-NF-κB pathway. J Cell Physiol. 2023;238:2063-2075.
[30] LIN X, XU F, ZHANG KW, et al. Acacetin Prevents Bone Loss by Disrupting Osteoclast Formation and Promoting Type H Vessel Formation in Ovariectomy-Induced Osteoporosis. Front Cell Dev Biol. 2022;10:796227.
[31] CHEN Y, ZHANG J, GE X, et al. Vitamin D receptor inhibits nuclear factor κB activation by interacting with IκB kinase β protein. J Biol Chem. 2013;288:19450-19458.
[32] SCHWARTZ C, WILLEBRAND R, HUBER S, et al. Eosinophil-specific deletion of IκBα in mice reveals a critical role of NF-κB-induced Bcl-xL for inhibition of apoptosis.Blood. 2015;125(25):3896-3904.
[33] XU Y, ZHANG S, LIAO X, et al. Circular RNA circIKBKB promotes breast cancer bone metastasis through sustaining NF-κB/bone remodeling factors signaling. Mol Cancer. 2021;20(1):98. |